Human Papillomavirus (HPV) Vaccine Market Report 2026

The human papillomavirus (hpv) vaccine market size has grown rapidly in recent years. It will grow from $6.57 billion in 2025 to $7.4 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to high prevalence of cervical cancer, limited awareness about hpv vaccination, government funding for immunization, availability of tetravalent and bivalent vaccines, rising healthcare infrastructure in developed regions.

The human papillomavirus (hpv) vaccine market size is expected to see rapid growth in the next few years. It will grow to $12.17 billion in 2030 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to increasing adoption of nonavalent vaccines, expansion of public-private healthcare partnerships, growth in awareness campaigns, technological advancements in vaccine delivery, rising investments in preventive healthcare. Major trends in the forecast period include increased hpv vaccination awareness, government immunization programs, expansion in emerging markets, development of next-generation hpv vaccines, partnerships between pharma companies and healthcare providers.

The rising prevalence of HPV-related diseases is anticipated to drive the expansion of the human papillomavirus (HPV) vaccine market in the coming years. HPV-related diseases are viral infections that commonly cause warts on the skin or mucous membranes. HPV vaccines are designed to specifically target high-risk HPV subtypes, thereby reducing the risk of HPV infection and the recurrence of associated diseases. For example, in February 2023, according to the National Cancer Institute, a US-based agency under the Department of Health and Human Services, approximately 13,960 women in the United States were expected to be diagnosed with invasive cervical cancer, with an estimated 4,310 deaths in 2023. In addition, about 7.7 new cases of cervical cancer per 100,000 women were diagnosed annually, along with a mortality rate of 2.2 per 100,000 women per year. Consequently, the growing burden of HPV-related diseases is contributing to the growth of the human papillomavirus vaccine market.

Major companies operating in the human papillomavirus vaccine market are emphasizing innovative approaches such as awareness campaigns to educate communities about the importance and benefits of HPV vaccination. Awareness campaigns are structured initiatives aimed at informing the public or specific populations about health issues, preventive measures, or medical interventions. For instance, in January 2023, the Family Planning Association of India, an India-based charity, launched a nationwide vaccination drive against cervical cancer targeting girls aged 9 to 14 years. This HPV vaccination initiative focuses on protecting girls and women from cervical cancer through the use of a quadrivalent vaccine that targets key HPV strains. The campaign aims to vaccinate approximately 50 million girls while increasing awareness and improving vaccine access across both urban and rural regions.

In August 2023, MSD, a US-based provider of vaccines and medicines operating under the Merck & Co., Inc. umbrella, partnered with Bio Farma to locally manufacture a four-valent HPV vaccine branded as NUSAGARD. Through this collaboration, MSD seeks to transfer its HPV vaccine technology to strengthen local production capabilities, enhance vaccine availability, and support Indonesia’s national immunization program. Bio Farma is an Indonesia-based company offering end-to-end pharmaceutical services, including vaccine research, development, manufacturing, and distribution.

Major companies operating in the human papillomavirus (hpv) vaccine market are Merck & Co Inc, GlaxoSmithKline plc, Serum Institute of India Pvt Ltd, Walvax Biotechnology Co Ltd, Beijing Wantai Biological Pharmacy Enterprise Co Ltd, Xiamen Innovax Biotech Co Ltd, Bharat Biotech International Ltd, Shanghai Zerun Biotech Co Ltd, Recbio Biotech, Yuxi Zerun Biotechnology Co Ltd, Innovax, Biofarma Co, Incepta Pharmaceuticals, PT Bio Farma, Instituto Butantan, Sinergium Biotech, BioMed Vaccine Technologies, Vaxart Inc., GeoVax, Recbio.

North America was the largest region in the human papillomavirus (HPV) vaccine market in 2025. The regions covered in the human papillomavirus (hpv) vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human papillomavirus (hpv) vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the human papillomavirus (HPV) vaccine market by increasing the cost of imported vaccines and raw materials, leading to higher production costs for manufacturers. Regions such as North America and Europe, which rely on imported vaccine components, are most affected, while government immunization programs face budget constraints. Vaccine types like nonavalent and tetravalent are particularly impacted due to complex manufacturing processes. However, tariffs have also encouraged local production and innovation, enabling some manufacturers to optimize supply chains and reduce dependency on imports.

The human papillomavirus (hpv) vaccine market research report is one of a series of new reports that provides human papillomavirus (hpv) vaccine market statistics, including human papillomavirus (hpv) vaccine industry global market size, regional shares, competitors with a human papillomavirus (hpv) vaccine market share, detailed human papillomavirus (hpv) vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the human papillomavirus (hpv) vaccine industry. This human papillomavirus (hpv) vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The Human Papillomavirus (HPV) vaccine is a vaccine designed to help prevent infection from specific strains of human papillomavirus (HPV). HPV vaccines are effective in preventing the majority of cervical, vaginal, and vulvar cancer cases.

The main types of human papillomavirus (HPV) vaccines include tetravalent, nonavalent, and bivalent vaccines. Tetravalent vaccines stimulate the body’s immune system to defend against four different antigens, such as four distinct viruses or microorganisms, thereby generating an immune response. The vaccines are used for indications including cervical cancer, anal cancer, vulvar and vaginal cancer, penile cancer, oropharyngeal cancer, and others, and are distributed through hospital pharmacies, retail pharmacies, government suppliers, and other channels. The key industry verticals involved include public and private alliances, government entities, physicians, and others.

The human papillomavirus (HPV) vaccine market consists of sales of gardasil 9, gardasil, and cervarix. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.